Cognizant, Microsoft collaborate to bring cloud-based solutions to the healthcare market

Microsoft Cloud for Healthcare and Cognizant’s TriZetto healthcare products aim to enhance transparency for consumers and increase interoperability for providers and payers

Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, says GlobalData

FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop

Todaro Robotics completes 2+ years partnership with Abwiz Bio

The milestone of operating continuously a very complex system for over two years has demonstrated the effectiveness of integrated laboratory automation solutions

mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma

Approx 800 million Indians do not have health coverage, says Expert

Government hospitals like AIIMS, KGMC & many more as per day OPD patients are 18-25 thousand

AnaBios acquires Cell Systems to expand human cell portfolio for drug discovery

Lonza and ABL Bio collaborate on development and manufacture of new bispecific antibody product

Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution

Philips and Northwell Health partner to standardize patient monitoring across the enterprise

New York State’s largest health system adopts Philips patient monitoring platform to drive integration and innovation for a better patient and staff experience and improved outcomes

TSCS team met All India Imam Organization Chief to discuss on thalassemia eradication in India

Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease

HSBC acquisition of SVB UK to unleash new opportunities in biotech sector, finds GlobalData

SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development